Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d treatment for acute brain ischemia

Gemma Llovera, Kerstin Hofmann, Stefan Roth, Angelica Salas-Pérdomo, Maura Ferrer-Ferrer, Carlo Perego, Elisa R. Zanier, Uta Mamrak, Andre Rex, Hélène Party, Véronique Agin, Claudine Fauchon, Cyrille Orset, Benoît Haelewyn, Maria Grazia De Simoni, Ulrich Dirnagl, Ulrike Grittner, Anna M. Planas, Nikolaus Plesnila, Denis VivienArthur Liesz

Research output: Contribution to journalArticlepeer-review


Numerous treatments have been reported to provide a beneficial outcome in experimental animal stroke models; however, these treatments (with the exception of tissue plasminogen activator) have failed in clinical trials. To improve the translation of treatment efficacy from bench to bedside, we have performed a preclinical randomized controlled multicenter trial (pRCT) to test a potential stroke therapy under circumstances closer to the design and rigor of a clinical randomized control trial. Anti-CD49d antibodies,which inhibit the migration of leukocytes into the brain, were previously investigated in experimental strokemodels by individual laboratories. Despite the conflicting results from four positive and one inconclusive preclinical studies, a clinical trial was initiated. To confirm the preclinical results and to test the feasibility of conducting a pRCT, six independent European research centers investigated the efficacy of anti-CD49d antibodies in two distinct mouse models of stroke in a centrally coordinated, randomized, and blinded approach. The results pooled from all research centers revealed that treatment with CD49d-specific antibodies significantly reduced both leukocyte invasion and infarct volume after the permanent distal occlusion of the middle cerebral artery, which causes a small cortical infarction. In contrast, anti-CD49d treatment did not reduce lesion size or affect leukocyte invasion after transient proximal occlusion of the middle cerebral artery, which induces large lesions. These results suggest that the benefits of immune-targeted approachesmay depend on infarct severity and localization. This study supports the feasibility of performing pRCTs.

Original languageEnglish
Article number299ra121
JournalScience Translational Medicine
Issue number299
Publication statusPublished - Aug 5 2015

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d treatment for acute brain ischemia'. Together they form a unique fingerprint.

Cite this